[go: up one dir, main page]

DE69630120D1 - Kristalle von fragmenten von cd40-liganden und deren verwendung - Google Patents

Kristalle von fragmenten von cd40-liganden und deren verwendung

Info

Publication number
DE69630120D1
DE69630120D1 DE69630120T DE69630120T DE69630120D1 DE 69630120 D1 DE69630120 D1 DE 69630120D1 DE 69630120 T DE69630120 T DE 69630120T DE 69630120 T DE69630120 T DE 69630120T DE 69630120 D1 DE69630120 D1 DE 69630120D1
Authority
DE
Germany
Prior art keywords
crystals
fragments
ligands
ligand
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630120T
Other languages
English (en)
Other versions
DE69630120T2 (de
Inventor
Mihail N Karpusas
Juswinder Singh
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE69630120D1 publication Critical patent/DE69630120D1/de
Publication of DE69630120T2 publication Critical patent/DE69630120T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
DE69630120T 1995-06-22 1996-06-21 Kristalle von fragmenten von cd40-liganden und deren verwendung Expired - Fee Related DE69630120T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44895P 1995-06-22 1995-06-22
US448P 1995-06-22
PCT/US1996/010664 WO1997000895A1 (en) 1995-06-22 1996-06-21 Crystals of fragments of cd40 ligand and their use

Publications (2)

Publication Number Publication Date
DE69630120D1 true DE69630120D1 (de) 2003-10-30
DE69630120T2 DE69630120T2 (de) 2004-04-08

Family

ID=21691579

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630120T Expired - Fee Related DE69630120T2 (de) 1995-06-22 1996-06-21 Kristalle von fragmenten von cd40-liganden und deren verwendung

Country Status (10)

Country Link
EP (1) EP0833847B1 (de)
JP (2) JPH11508262A (de)
AT (1) ATE250630T1 (de)
AU (1) AU6337296A (de)
CA (1) CA2224812A1 (de)
DE (1) DE69630120T2 (de)
DK (1) DK0833847T3 (de)
ES (1) ES2202455T3 (de)
PT (1) PT833847E (de)
WO (1) WO1997000895A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
EP1754490A3 (de) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
CA2331295A1 (en) 1998-05-12 1999-11-18 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
CN112151122B (zh) * 2020-09-10 2025-02-21 国家纳米科学中心 结构未知晶体衍射能力的计算方法及物相定量分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
CA2153806C (en) * 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene

Also Published As

Publication number Publication date
PT833847E (pt) 2004-02-27
WO1997000895A1 (en) 1997-01-09
JPH11508262A (ja) 1999-07-21
AU6337296A (en) 1997-01-22
ES2202455T3 (es) 2004-04-01
DK0833847T3 (da) 2003-12-29
EP0833847A1 (de) 1998-04-08
EP0833847B1 (de) 2003-09-24
CA2224812A1 (en) 1997-01-09
ATE250630T1 (de) 2003-10-15
DE69630120T2 (de) 2004-04-08
JP2006188541A (ja) 2006-07-20
HK1010085A1 (en) 1999-06-11

Similar Documents

Publication Publication Date Title
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
ATE364592T1 (de) Tyrosinderivate
DE69433406T2 (de) Antikörper gegen cd40
DE60141950D1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
DE68916512D1 (de) Zusammensetzung zur Verminderung von postoperativen Adhäsionen und ihre Verwendung.
ATE295519T1 (de) Behandlung von kohlenwasserstoffgas
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
BG101747A (en) Cycloalkanopyridines
ATE399007T1 (de) Raf kinase hemmer
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
ATE388399T1 (de) Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen
DE69630120D1 (de) Kristalle von fragmenten von cd40-liganden und deren verwendung
ATE332356T1 (de) Verwendung von metallkomplexverbindungen als oxidationskatalysatoren
TR200003606T2 (tr) Yüksek çinko oluşumlu yeni insülin benzerleri.
DK1047669T3 (da) Perfluor-N-alkylsulfonsyrederivater
ATE469169T1 (de) Erythrovirus und ihre verwendung
HK1039341A1 (zh) α1β1合成(「α1β1」)I-领域的结晶体及其使用
YU36104A (sh) Kristalna struktura fosfodiesteraza 5 i njihova upotreba
ATE184199T1 (de) Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US

8339 Ceased/non-payment of the annual fee